Accéder au contenu
Merck
Toutes les photos(2)

Key Documents

CIX001

Sigma-Aldrich

ComInnex IAP Ligand Library

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Code UNSPSC :
41116105
Nomenclature NACRES :
NA.22

Forme

solid (powder or film on well wall)

Niveau de qualité

Pertinence de la réaction

reagent type: ligand

Concentration

125 μg/well

Adéquation

suitable for H-NMR
suitable for LC-MS

Température de stockage

2-8°C

Application

The ComInnex IAP Ligand Library is an 80-member collection of in-silico-derived ligands targeting cellular inhibitor of apoptosis protein 1 (cIAP1). cIAP1 is an E3 ligase of interest for the development of protein degraders, specifically called specific and non-genetic IAP-dependent protein erasers (SNIPERs).

Based on the SAR rules outlined in IAP antagonist research, the binding tetrapeptide anchor of the natural SMAC inhibitor protein of IAPs (AVPI and AVPF) was used in identification of novel derivatives designed by 3D similarity.

The initial library was filtered via in silico IFD methods by docking to the BIR3 domain of the IAP crystal structures. The highest binding derivatives were selected and collected in a screening library, including the natural binding tetrapeptides and known MV1 reference compounds. IAP in silico leads are an optimal collection to begin IAP lead discovery at the bench for eventual development into bifunctional protein degraders. With the proper assay setup to measure protein degradation or protein-protein interactions (PPIs), the ComInnex IAP Ligand Library can also be a platform for molecular glue discovery.

Learn more about this library: Accelerating IAP Lead Discovery for Targeted Protein Degradation

To view a complete list of compounds in the library, including sdf, visit the CIX001 Plate Map.

To streamline the assessment of these in silico leads for target-specific bifunctional degraders, three IAP ligands with the highest docking scores were also prepared as degrader building blocks for simple attachment of a target warhead.

Actions biochimiques/physiologiques

80 compounds are arranged in 96-microtube format with two open rows for screening controls if using liquid handling setups. One compound per tube (125 μg in solid form). Compound concentration in assays will vary depending on assay type, but common screening library stock solutions are 2 mM or 10 mM in DMSO.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Keiichiro Okuhira et al.
Molecular pharmacology, 91(3), 159-166 (2016-12-15)
Development of novel small molecules that selectively degrade pathogenic proteins would provide an important advance in targeted therapy. Recently, we have devised a series of hybrid small molecules named SNIPER (specific and nongenetic IAP-dependent protein ERaser) that induces the degradation
Yukihiro Itoh et al.
Bioorganic & medicinal chemistry letters, 22(13), 4453-4457 (2012-06-05)
Protein knockdown can be achieved by the use of a small molecule that possesses affinity for both the target protein and ubiquitin ligase. We have designed such a degradation-inducing molecule targeting cIAP1 and CRABP-II, which are involved in proliferation of
Norihito Shibata et al.
Cancer science, 108(8), 1657-1666 (2017-05-31)
Chromosomal translocation occurs in some cancer cells, which results in the expression of aberrant oncogenic fusion proteins that include BCR-ABL in chronic myelogenous leukemia (CML). Inhibitors of ABL tyrosine kinase, such as imatinib and dasatinib, exhibit remarkable therapeutic effects, although
Mikihiko Naito et al.
Drug discovery today. Technologies, 31, 35-42 (2019-06-16)
The induction of protein degradation by chimeric small molecules represented by proteolysis-targeting chimeras (PROTACs) is an emerging approach for novel drug development. We have developed a series of chimeric molecules termed specific and non-genetic inhibitor of apoptosis protein (IAP)-dependent protein
Nobumichi Ohoka et al.
The Journal of biological chemistry, 292(11), 4556-4570 (2017-02-06)
Many diseases, especially cancers, result from aberrant or overexpression of pathogenic proteins. Specific inhibitors against these proteins have shown remarkable therapeutic effects, but these are limited mainly to enzymes. An alternative approach that may have utility in drug development relies

Articles

Plate of 80 ligands against E3 ligase IAP designed by ComInnex; allows creation of bifunctional targeted protein degraders or molecular glues.

Plate of 80 ligands against E3 ligase IAP designed by ComInnex; allows creation of bifunctional targeted protein degraders or molecular glues.

Plate of 80 ligands against E3 ligase IAP designed by ComInnex; allows creation of bifunctional targeted protein degraders or molecular glues.

Plate of 80 ligands against E3 ligase IAP designed by ComInnex; allows creation of bifunctional targeted protein degraders or molecular glues.

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique